{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:27:46Z","timestamp":1789932466093,"version":"4.0.1"},"reference-count":38,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2016,3,1]]},"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tachykinins have been implicated in the pathophysiology of IBS with diarrhoea (IBS-D). Our aim was to study the efficacy and safety of ibodutant, a selective neurokinin-2 (NK2) receptor antagonist, in patients with IBS-D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multinational double-blind, placebo-controlled study recruited 559 patients with IBS-D according to Rome III criteria. After a 2-week treatment-free run-in, patients were randomised to ibodutant 1\u2005mg, 3\u2005mg, 10\u2005mg or placebo once daily for eight consecutive weeks. Responders were those with a combined response of satisfactory relief (weekly binary question yes\/no) of overall IBS symptoms and abdominal pain\/discomfort on \u226575% weeks (primary end point). Secondary end points included abdominal pain and stool pattern. Data were also analysed according to US Food and Drug Administration (FDA)-approved interim end points (improvement of pain and stool consistency). Safety was assessed by monitoring adverse events and laboratory tests. Prespecified statistical analysis involved the whole group as well as gender subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Demographics and baseline characteristics were comparable for all treatment arms. In the overall population, responsiveness tended to increase with escalating ibodutant doses. In the prespecified analysis by gender, ibodutant 10\u2005mg demonstrated significant superiority over placebo in females (p=0.003), while no significant effect occurred in males. This was confirmed for secondary end points and for the responder analysis according to FDA-approved end points. The tolerability and safety of ibodutant was excellent at all doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ibodutant showed dose-dependent efficacy response in IBS-D, reaching statistical significance at the 10\u2005mg dose in female patients. The safety and tolerability profile of ibodutant was similar to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT01303224.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2015-310683","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T11:40:59Z","timestamp":1499773259000},"page":"1403-1413","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS"],"prefix":"10.1136","volume":"66","clinical-trial-number":[{"clinical-trial-number":"nct01303224","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"J","family":"Tack","sequence":"first","affiliation":[{"name":"Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Menarini Research & Business Service GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Tonini","sequence":"additional","affiliation":[{"name":"Menarini Ricerche S.p.A, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Scartoni","sequence":"additional","affiliation":[{"name":"Menarini Ricerche S.p.A, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Capriati","sequence":"additional","affiliation":[{"name":"Menarini Ricerche S.p.A, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"Maggi","sequence":"additional","affiliation":[{"name":"Menarini Ricerche S.p.A, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"key":"2025121304281237000_66.8.1403.1","unstructured":"Drossman DA , Corazziari E , Delvaux M , et al . Rome III. The functional gastrointestinal disorders. 3rd edn. Degnon Associates, 2006."},{"key":"2025121304281237000_66.8.1403.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02671.x"},{"key":"2025121304281237000_66.8.1403.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2005.02.008"},{"key":"2025121304281237000_66.8.1403.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2006.01006.x"},{"key":"2025121304281237000_66.8.1403.5","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.119446"},{"key":"2025121304281237000_66.8.1403.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"2025121304281237000_66.8.1403.7","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.69"},{"key":"2025121304281237000_66.8.1403.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2313"},{"key":"2025121304281237000_66.8.1403.9","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.223"},{"key":"2025121304281237000_66.8.1403.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-014-0966-7"},{"key":"2025121304281237000_66.8.1403.11","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2012.645537"},{"key":"2025121304281237000_66.8.1403.12","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903379530"},{"key":"2025121304281237000_66.8.1403.13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs335"},{"key":"2025121304281237000_66.8.1403.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.05961.x"},{"key":"2025121304281237000_66.8.1403.15","doi-asserted-by":"publisher","DOI":"10.1002\/cne.21359"},{"key":"2025121304281237000_66.8.1403.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-007-7148-1"},{"key":"2025121304281237000_66.8.1403.17","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90892-T"},{"key":"2025121304281237000_66.8.1403.18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF00169740","article-title":"Human isolated ileum: motor responses of the circular muscle to electrical field stimulation and exogenous neuropeptides","volume":"341","author":"Maggi","year":"1990","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2025121304281237000_66.8.1403.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00205-7"},{"key":"2025121304281237000_66.8.1403.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2008.06267.x"},{"key":"2025121304281237000_66.8.1403.21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703040"},{"issue":"1","key":"2025121304281237000_66.8.1403.22","first-page":"69","article-title":"Tachykinin receptors and gastrointestinal motility: focus on humans","volume":"12","author":"Lecci","year":"2008","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025121304281237000_66.8.1403.23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.autneu.2006.02.014","article-title":"Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human","volume":"126\u2013127","author":"Lecci","year":"2006","journal-title":"Auton Neurosci"},{"key":"2025121304281237000_66.8.1403.24","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12616"},{"key":"2025121304281237000_66.8.1403.25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704217"},{"key":"2025121304281237000_66.8.1403.26","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12616"},{"key":"2025121304281237000_66.8.1403.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.08.021"},{"key":"2025121304281237000_66.8.1403.28","unstructured":"Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. CPMP\/EWP\/785\/97, London 19 March 2003."},{"key":"2025121304281237000_66.8.1403.29","unstructured":"Guidance for Industry-Irritable Bowel Syndrome- Clinical evaluation of drugs for treatment; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). May 2012."},{"key":"2025121304281237000_66.8.1403.30","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709011203"},{"key":"2025121304281237000_66.8.1403.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02938.x"},{"key":"2025121304281237000_66.8.1403.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00459.x"},{"key":"2025121304281237000_66.8.1403.33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/14656566.2016.1118052","article-title":"Rifaximin and eluxadoline\u2014newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?","volume":"17","author":"Cash","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2025121304281237000_66.8.1403.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00519.x"},{"key":"2025121304281237000_66.8.1403.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.03.004"},{"key":"2025121304281237000_66.8.1403.36","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12151"},{"key":"2025121304281237000_66.8.1403.37","doi-asserted-by":"crossref","unstructured":"Wolf-Johnston AS , Kullmann FA , Beckel JM , et al . Effect of ibodutant, a neurokinin NK2 receptor antagonist, on gender-related influences following induction of trinitrobenzenesulfonic acid-induced colitis in the Guinea Pig. Gastroenterology 148:S-777 (abstract).","DOI":"10.1016\/S0016-5085(15)32650-0"},{"key":"2025121304281237000_66.8.1403.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01941.x"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2015-310683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T12:28:21Z","timestamp":1765628901000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2015-310683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,7,11]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1136\/gutjnl-2015-310683"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2015-310683","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]}}}